10472-97-6

Usage

Chemical Properties

colourless liquid

InChI:InChI=1/C14H22O/c15-13-9-4-2-1-3-6-10-14-11-7-5-8-12-14/h5,7-8,11-12,15H,1-4,6,9-10,13H2

Upstream product

• 100863-10-3 trans-8-Phenyl-octen-⁽⁴⁾-ol-⁽¹⁾ 
• 201230-82-2 carbon monoxide 
• 536-74-3 phenylacetylene 
• 502929-60-4 8-phenyloctyl tetrahydropyranyl ether 
• 502929-58-0 8-phenyl-7-octenyl tetrahydropyranyl ether 
• 5631-95-8 2,3-dichlorotetrahydro-2H-pyran 
• 637-59-2 1-Bromo-3-phenylpropane 
• 26547-51-3 8-phenyloctanoic acid 

Downstream Products

• 54646-75-2 1-bromo-8-phenyloctane 
• 62116-89-6 8-phenyl-octanal 
• 260050-36-0 5-(7-phenyl-heptyl)-4-tosyl-2-oxazoline 
• 96964-45-3 2-(8-phenyloctyl) benzaldehyde 
• 96964-42-0 2-[2-(8-phenyloctyl)phenyl]-4,4-dimethyloxazoline 
• 96964-40-8 SKF 102922 
• 102373-00-2 1-Phenyl-8-(4-nitro-2-methoxy-phenoxy)-octan 
• 15382-78-2 1-Phenyl-8-<4-amino-2-methoxy-phenoxy>-octan 
• 224771-49-7 2-(8-phenyloct-1-yl)oxy-5-(pyrid-3-ylmethyl)pyrimidin-4-one 
• 2930-05-4 Benzyloxymethyl-oxiran 
• 61440-32-2 8-phenyloctyl chloride 
• 1021877-99-5 C₁₄H₂₀⁽²⁾H₂O 
• 1048703-33-8 8-phenyloctyl 2,2,4,4-tetramethyl-1,3-oxazolidine-3-carboxylate 
• 224775-70-6 8-(4-Acetylphenyl)octan-1-ol 

Relevant academic research and scientific papers

Selective antiproliferative activity of caffeic acid phenethyl ester analogues on highly liver-Metastatic murine colon 26-L5 carcinoma cell line

Caffeic acid phenethyl ester (CAPE, 2) and its 20 analogues (1, 3-21) were prepared. These esters were tested by MTT assay on growth of murine colon 26-L5 carcinoma, murine B16-BL6 malonoma, murine Lewis lung carcinoma, human HT-1080 fibrosarcoma, human lung A549 adenocarcinoma, and human cervix HeLa adenocarcinoma cell lines. It was found that CAPE analogues possessed selective antiproliferative activity toward highly liver-metastatic murine colon 26-L5 carcinoma cell line. Among them, 4-phenylbutyl caffeate (4), (Z)-8-phenyl-7-octenyl (10a) and (E)-8-phenyl-7-octenyl (10b) caffeate showed the most potent antiproliferative activity (EC50 value, 0.02μM). In addition, CAPE (2) induced DNA fragmentation at concentrations of 1 to 10μg/mL towards murine colon 26-L5 carcinoma cells. Copyright

LEUKOTRIENE ANTAGONISTS

This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists, processes for the preparation thereof, and pharmaceutical compositions containing such compounds.This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Leukotriene antagonists

Leukotriene antagonist thiadiazoles have been prepared.

Quaternary ammonium compounds having muscle relaxation activity

A quaternary ammonium having a muscle relaxation activity compound represented by the formula (I): STR1 wherein R1 represents a methylene, a lower alkylenoxy, a lower alkenylene, a lower alkynylene, --CO--, --COO--, a lower alkylene carbonyloxy, --CH(OR5)--, a lower alkylenecarbonyl, a hydroxy lower alkylene, --O--, --S--, --SO--, or --SO2 --; R2 represents a hydrogen atom, a hydroxy lower alkyl, an aldehyde, a lower alkyl carbonyl, --NO2, or --NHR6 ; R3 represents a hydrogen atom of a group --R1 --(CH2)a --[CH(CH2 A)--CH2 ]b --A; R4 represents an anion; R5 and R6 represent a hydrogen atom or a acetyl; A represents a quaternary ammonium group; a represents an integer of 1 to 8; b represents 0 or 1; m represents an integer of 1 to 4; and (Z) represents a trivalent benzene ring, a trivalent naphthalene ring, a trivalent diphenyl or a trivalent ethane radical.

LEUKOTRIENE ANTAGONISTS CONTAINING TETRAZOLYL GROUPS

This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Leukotriene antagonists

This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists, pharmaceutical compositions containing such compounds, and methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Leukotriene antagonists

This invention relates to alkanoic acid compounds having phenyl and sulfinyl or sulfonyl substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. The invention also relates to the use of such compound for treatment of diseases in which leukotrienes are a factor.